Wednesday, October 20, 2021

Metropolis Healthcare to acquire Hitech Diagnostic Centre – Express Healthcare



Read Article

Deal includes cash consideration of Rs. 511 crores, acquisition expected to complete within three months, and will strengthen Metropolis’ position as the second largest diagnostics company in India and largest brand in South and West India

Metropolis Healthcare’s Board of Directors has approved the acquisition of 100 per cent equity of Dr Ganesan’s Hitech Diagnostic Centre (Hitech) in a combination of cash and stock deal. The entity is a debt free company and the acquisition is expected to be completed within three months. The acquisition s expected to strengthen Metropolis’ position as the second largest diagnostics company in India and largest brand in South and West India.

Cash consideration will be Rs. 511 crores and Metropolis will issue up to 4,95,000 equity shares of Face Value Rs.2/- each on preferential basis, subject to shareholders approval, to the promoter group of Hitech. The cash consideration will be funded through internal accruals and debt of up to Rs. 300 crores.
Dr. Ganesan, promoter and founder, will be part of the leadership team for the next few years to enable a smooth transition and integration with Metropolis.

The acquisition will reportedly allow Metropolis to increase its B2C business in focus cities of Chennai and Bengaluru and benefit through optimisation of operational costs in the areas of procurement, supply chain, administration and support resource, laboratory network and back office infrastructure. It will further allow the Metropolis brand to make deeper inroads in different customer segments across key markets in South India.

Metropolis will get access to 31 laboratories including three NABL and ICMR accredited laboratories and 68 collection centres of Hitech, spread across the states of Tamil Nadu, Karnataka, Kerala, Andhra Pradesh and the Union Territory of Pondicherry.

Established in 1986, Hitech is the second largest player in Chennai behind Metropolis and is a leader in non-Chennai markets in the state of Tamil Nadu. It is a significant player in Bengaluru market. Catering to the mid-segment of the market with a large B2C footprint, it has a test menu of 1,100+ tests ranging from routine to highly impenetrable molecular and genetic assays. In FY20, 59 per cent of the test menu was towards blood biochemistry and endocrinology. Revenue for FY20 stood at Rs. 83.3 crores having an EBITDA margin profile similar to Metropolis. For 9MFY21, as per management estimates, the revenue growth has been ~50 per cent+ with higher EBITDA margins partly aided by the current pandemic situation.



Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...